Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

Resverlogix (TSX:RVX) has announced that Dr. Jeffrey Cummings, founding director of the Cleveland Clinic Lou Ruvo Brain Health Center, gave an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease.

As quoted in the press release:

During the presentation, Dr. Cummings discussed certain risk factors – including diabetes, coronary heart disease and heart failure – associated with an increased risk of cognitive decline, cognitive impairment or dementia. Furthermore, Dr. Cummings delivered the hypothesis that dementia risk in diabetes and cardiovascular disease patients is caused by transcriptional disturbances at the epigenetic level.

The presentation also highlighted the potential of the Company’s small molecule – apabetalone, a selective bromodomain and extra-terminal inhibitor – to regulate disease-associated genes, proteins and pathways related to neuroinflammation and neurodegeneration, the BETonMACE study design, the cognition subgroup study methods and patient baseline characteristics.

The BETonMACE trial is currently expected to be completed within the first half of calendar 2019. The study is an event-based trial and will continue until at least 250 major adverse cardiac events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and stroke, have occurred. Third party adjudication of all MACE events are anticipated to be available within two to three months past trial completion. The topline results of the study will be made available shortly thereafter.

Click here to read the full press release.